What is Leerink Partnrs’ Estimate for LRMR FY2025 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Investment analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Larimar Therapeutics in a research note issued on Wednesday, September 3rd. Leerink Partnrs analyst J. Park now expects that the company will post earnings of ($1.80) per share for the year, down from their previous forecast of ($1.79). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.15) per share. Leerink Partnrs also issued estimates for Larimar Therapeutics’ FY2027 earnings at ($1.96) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.18) EPS.

LRMR has been the topic of a number of other reports. Guggenheim reissued a “buy” rating and issued a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. JMP Securities cut their price objective on Larimar Therapeutics from $22.00 to $18.00 and set a “market outperform” rating on the stock in a research note on Friday, August 15th. Citigroup reissued a “buy” rating on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Finally, Wedbush cut their price objective on Larimar Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 24th. Nine investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, Larimar Therapeutics has a consensus rating of “Buy” and an average price target of $18.43.

Larimar Therapeutics Stock Performance

Shares of LRMR stock opened at $3.87 on Monday. The stock’s 50 day simple moving average is $3.61 and its 200 day simple moving average is $2.82. Larimar Therapeutics has a twelve month low of $1.61 and a twelve month high of $9.50. The company has a market capitalization of $320.36 million, a price-to-earnings ratio of -2.48 and a beta of 0.91.

Larimar Therapeutics (NASDAQ:LRMR) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.06.

Insider Buying and Selling

In other Larimar Therapeutics news, Director James E. Flynn purchased 9,375,000 shares of the company’s stock in a transaction on Thursday, July 31st. The shares were bought at an average cost of $3.20 per share, with a total value of $30,000,000.00. Following the transaction, the director directly owned 9,538,945 shares in the company, valued at approximately $30,524,624. This represents a 5,718.38% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 4.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. ProShare Advisors LLC bought a new position in Larimar Therapeutics in the 4th quarter worth approximately $58,000. Janus Henderson Group PLC increased its position in shares of Larimar Therapeutics by 15.7% during the fourth quarter. Janus Henderson Group PLC now owns 6,443,286 shares of the company’s stock valued at $24,936,000 after purchasing an additional 876,431 shares during the period. Alyeska Investment Group L.P. increased its position in shares of Larimar Therapeutics by 46.6% during the first quarter. Alyeska Investment Group L.P. now owns 1,442,473 shares of the company’s stock valued at $3,101,000 after purchasing an additional 458,396 shares during the period. Cubist Systematic Strategies LLC increased its position in shares of Larimar Therapeutics by 278.8% during the fourth quarter. Cubist Systematic Strategies LLC now owns 233,873 shares of the company’s stock valued at $905,000 after purchasing an additional 172,131 shares during the period. Finally, Northern Trust Corp increased its position in shares of Larimar Therapeutics by 8.6% during the fourth quarter. Northern Trust Corp now owns 376,458 shares of the company’s stock valued at $1,457,000 after purchasing an additional 29,924 shares during the period. 91.92% of the stock is owned by institutional investors.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.